The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Effects of Estrogen With and Without Progestin on Urinary Incontinence
Abstract
CONTEXT: Menopausal hormone therapy has long been credited with many benefits beyond the indications of relieving hot flashes, night sweats, and vaginal dryness, and it is often prescribed to treat urinary incontinence (UI). OBJECTIVE: To assess the effects of menopausal hormone therapy on the incidence and severity of symptoms of stress, urge, and mixed UI in healthy postmenopausal women. DESIGN, SETTING, AND PARTICIPANTS: Women's Health Initiative multicenter double-blind, placebo-controlled, randomized clinical trials of menopausal hormone therapy in 27,347 postmenopausal women aged 50 to 79 years enrolled between 1993 and 1998, for whom UI symptoms were known in 23,296 participants at baseline and 1 year. INTERVENTIONS: Women were randomized based on hysterectomy status to active treatment or placebo in either the estrogen plus progestin (E + P) or estrogen alone trials. The E + P hormones were 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (CEE + MPA); estrogen alone consisted of 0.625 mg/d of conjugated equine estrogen (CEE). There were 8506 participants who received CEE + MPA (8102 who received placebo) and 5310 who received CEE alone (5429 who received placebo). MAIN OUTCOME MEASURES: Incident UI at 1 year among women without UI at baseline and severity of UI at 1 year among women who had UI at baseline. RESULTS: Menopausal hormone therapy increased the incidence of all types of UI at 1 year among women who were continent at baseline. The risk was highest for stress UI (CEE + MPA: relative risk [RR], 1.87 [95% confidence interval {CI}, 1.61-2.18]; CEE alone: RR, 2.15 [95% CI, 1.77-2.62]), followed by mixed UI (CEE + MPA: RR, 1.49 [95% CI, 1.10-2.01]; CEE alone: RR, 1.79 [95% CI, 1.26-2.53]). The combination of CEE + MPA had no significant effect on developing urge UI (RR, 1.15; 95% CI, 0.99-1.34), but CEE alone increased the risk (RR, 1.32; 95% CI, 1.10-1.58). Among women experiencing UI at baseline, frequency worsened in both trials (CEE + MPA: RR, 1.38 [95% CI, 1.28-1.49]; CEE alone: RR, 1.47 [95% CI, 1.35-1.61]). Amount of UI worsened at 1 year in both trials (CEE + MPA: RR, 1.20 [95% CI, 1.06-1.36]; CEE alone: RR, 1.59 [95% CI, 1.39-1.82]). Women receiving menopausal hormone therapy were more likely to report that UI limited their daily activities (CEE + MPA: RR, 1.18 [95% CI, 1.06-1.32]; CEE alone: RR, 1.29 [95% CI, 1.15-1.45]) and bothered or disturbed them (CEE + MPA: RR, 1.22 [95% CI, 1.13-1.32]; CEE alone: RR, 1.50 [95% CI, 1.37-1.65]) at 1 year. CONCLUSIONS: Conjugated equine estrogen alone and CEE + MPA increased the risk of UI among continent women and worsened the characteristics of UI among symptomatic women after 1 year. Conjugated equine estrogen with or without progestin should not be prescribed for the prevention or relief of UI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Design of the Women’s Health Initiative Clinical Trial and Observational Study
(1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,585
Measurement Characteristics of the Women’s Health Initiative Food Frequency Questionnaire
Patterson, R. E., Kristal, A. R., Tinker, L. F., Carter, R. A., Bolton, M. P., & Agurs-Collins, T. (1999) · Annals of Epidemiology · doi:10.1016/s1047-2797(98)00055-6 · Cited by 1,025
The women's health initiative recruitment methods and results
Hays, J., Hunt, J. R., Hubbell, F. A., Anderson, G. L., Limacher, M., Allen, C., & Rossouw, J. E. (2003) · Annals of Epidemiology · doi:10.1016/s1047-2797(03)00042-5 · Cited by 742
Prevalence of urinary incontinence and associated risk factors in postmenopausal women
Brown, J. (1999) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(99)00263-x · Cited by 410
Estrogen receptors in the human female lower urinary tract
Iosif, C. S., Batra, S. C., Ek, A., & Åstedt, B. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90710-9 · Cited by 383
Postmenopausal hormones and incontinence: the heart and Estrogen/Progestin Replacement Study
Grady, D. (2001) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(00)01115-7 · Cited by 364
Epidemiology and natural history of urinary incontinence in women
Hunskaar, S., Burgio, K., Diokno, A., Herzog, A. R., Hjälmås, K., & Lapitan, M. C. (2003) · Urology · doi:10.1016/s0090-4295(03)00755-6 · Cited by 355
Urinary incontinence in older women: Who is at risk?
BROWN, J., SEELEY, D., FONG, J., BLACK, D., ENSRUD, K., & GRADY, D. (1996) · Obstetrics & Gynecology · doi:10.1016/0029-7844(96)00013-0 · Cited by 353
Fantl, J. A., Cardozo, L., & McClish, D. K. (1994) · PubMed · Cited by 337
Prevalence of Genitourinary Symptoms in the Late Menopause
Iosif, C. S., & Bekassy, Z. (1984) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.3109/00016348409155509 · Cited by 304
Urinary incontinence predictors and life impact in ethnically diverse perimenopausal women
Sampselle, C. (2002) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(02)02241-x · Cited by 234
Efficacy of estrogen supplementation in the treatment of urinary incontinence
ANDREWFANTL, J., BUMP, R., ROBINSON, D., MCCLISH, D., & WYMAN, J. (1996) · Obstetrics & Gynecology · doi:10.1016/0029-7844(96)00281-5 · Cited by 230
Fornell, E. U., Wingren, G., & KjØlhede, P. (2004) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1080/j.0001-6349.2004.00367.x · Cited by 217
Grodstein, F., Fretts, R., Lifford, K., Resnick, N., & Curhan, G. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/s0002-9378(03)00361-2 · Cited by 209
Oestrogens for urinary incontinence in women
Moehrer, B., Hextall, A., & Jackson, S. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001405 · Cited by 176
Swithinbank, L. V., Donovan, J., du Heaume, J. C., Rogers, C. A., James, M., Yang, Q., & Abrams, P. (1999) · Europe PMC (PubMed Central) · Cited by 148
Thorn, D. H., & Brown, J. S. (1998) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1998.tb06009.x · Cited by 130
Short‐Term Variability of Self Report of Incontinence in Older Persons
Resnick, N. M., Beckett, L. A., Branch, L. G., Scherr, P. A., & Wetle, T. T. (1994) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1994.tb04953.x · Cited by 57
Griebling, T. L., & Nygaard, I. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70251-6 · Cited by 45
Urinary incontinence in primary care: A comparison of older African-American and Caucasian women
Novielli, K. D., Simpson, Z., Hua, G., Diamond, J. J., Sultana, C. J., & Paynter, N. P. (2003) · International Urology and Nephrology · doi:10.1023/b:urol.0000022868.73066.9a · Cited by 17
Cited by
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., et al. (2013) · JAMA · doi:10.1001/jama.2013.278040 · Cited by 1,650
Self-citationThe 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Metadata
- Authors
- Hendrix, S. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-02-23
- Volume
- 293
- Issue
- 8
- Pages
- 935
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2140643650
- Cited by
- 509
- References
- 22
- FWCI
- 26.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.